To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug ...

BeOne Medicines (NASDAQ:ONC) used an investor event at ASCO to outline what executives described as a new phase of growth ...

Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor – palbociclib, ribociclib or abemaciclib – maintained ...

Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor ...

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival ...

Rodrigo Munhoz, MD, of the Oncology Center-Hospital Sírio-Libanês of São Paulo, Brazil, commented that by "meeting its ...

The American Society of Clinical Oncology (ASCO) and Ryght AI are teaming up to identify research sites for an ASCO clinical ...

Abemaciclib significantly prolonged PFS compared with placebo for patients with advanced dedifferentiated liposarcoma, ...

Gedatolisib plus fulvestrant and palbociclib (the “gedatolisib-triplet”) reduced the risk of disease progression or death by 50% vs. alpelisib ...

AstraZeneca Plc AZN on Tuesday reported updated Phase 3 SERENA-6 trial results showing that camizestrant combined with a CDK4 ...

Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing ...